Evidence map›Paper›PMID 41201536›Full record

ArticleJournal of gastroenterology2026

Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.

Atsushi Yoshida, Tomohisa Takagi, Kousaku Kawashima, Kei Moriya, Shigeki Bamba, Shintaro Sagami, Tomoyuki Hayashi, Motoki Kaneko, Takeo Naito, Shuji Kanmura and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Atsushi YoshidaCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan. atsushi-yoshida@ofunachuohp.net.ORCID 0009-0009-9333-6729
Tomohisa TakagiMolecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kousaku KawashimaInflammatory Bowel Disease Center, Shimane University Hospital, Izumo, Japan.
Kei MoriyaNara Prefecture General Medical Center, Nara, Japan.
Shigeki BambaDepartment of Fundamental Nursing, Shiga University of Medical Science, Otsu, Japan.
Shintaro SagamiCenter for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato, Japan.
Tomoyuki HayashiInflammatory Bowel Disease Center, Kanazawa University Hospital, Kanazawa, Japan.
Motoki KanekoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Takeo NaitoDepartment of Gastroenterology, Tohoku University Hospital, Sendai, Japan.
Shuji KanmuraDivision of Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Kohei AsaedaMolecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shunji IshiharaInflammatory Bowel Disease Center, Shimane University Hospital, Izumo, Japan.
Shinsaku NagamatsuNara Prefecture General Medical Center, Nara, Japan.
Yutaka EndoCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan.
Fumiaki UenoCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan.
Toshio MorizaneCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan.
Katsuyoshi MatsuokaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
Toshifumi HibiCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to evaluate the predictive value of protease-3 (PR3)-anti-neutrophil cytoplasmic antibodies (ANCAs) and myeloperoxidase (MPO)-ANCA for primary nonresponse (PNR) to biologic agents in patients with ulcerative colitis (UC).

methodsA multicenter, prospective cohort study was conducted. Patients with UC who initiated biologic agents (anti-TNF, anti-integrin, or anti-IL12/23 agents) as their first-line therapy were enrolled. PNR was defined as failure to achieve a partial Mayo Score improvement of at least 2 points by weeks 14-16 or necessitating treatment modification. Logistic regression identified PNR predictors.

resultsAmong 95 biologic-naïve UC patients, 38 received anti-TNF, 39 received anti-integrin, and 18 received anti-IL12/23 agents. PR3-ANCA positivity was observed in 47.4% of anti-TNF recipients. The PNR rate among PR3-ANCA-positive patients receiving anti-TNF therapy was 66.7%, significantly higher than in PR3-ANCA-negative patients (25.0%, P = 0.02). Multivariate logistic regression confirmed PR3-ANCA as an independent risk factor for PNR to anti-TNF therapy (OR 5.61; 95% CI 1.37-26.82; P = 0.02). By contrast, PR3-ANCA did not predict PNR to anti-integrin therapy, but the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammatory index (SII) were identified as significant predictors. Only one of 95 patients tested positive for MPO-ANCA, precluding statistical analysis for its association with PNR.

conclusionIn patients with UC, PR3-ANCA is a significant predictor of PNR to anti-TNF therapy, but not to anti-integrin therapy. PLR and SII may predict PNR to anti-integrin therapy. PR3-ANCA could aid biologic selection, optimizing personalized UC treatment and healthcare resource utilization.

Indexed as

Antibodies, Antineutrophil CytoplasmicBiological ProductsColitis, UlcerativeAdultFemaleHumansIntegrinsLogistic ModelsMaleMiddle AgedPeroxidasePredictive Value of TestsProspective StudiesRisk FactorsTumor Necrosis Factor-alphaAntibodies, Antineutrophil CytoplasmicBiological ProductsIntegrinsPeroxidaseTumor Necrosis Factor-alphaANCAInflammatory bowel diseaseLymphocytePlateletPrognostic factor

Identifiers

PMID41201536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.